Региональные особенности основных показателей метаболизма углеводов у молодых жителей различных климатогеографических зон проживания

Daily intraperitoneal injection of cadmium chloride (0.25 or 1 mg/kg) for 21 or 45 days into rats significantly stimulated the activities of hepatic pyruvate carboxylase, phosphoenolpyruvate carboxykinase, fructose-1, 6-diphosphatase, and glucose-6-phosphatase, increased the concentrations of glucose and urea in the blood, and decreased the levels of glycogen in the liver. Whereas chronic cadmium treatment failed to alter adenosine-3',5'-monophosphate phosphodiesterase (phosphodiesterase) activity, the endogenous levels of cyclic AMP (cAMP) and the activity of basal- and fluoride-stimulated forms of hepatic adenylate cyclase (AC) were markedly increased in cadmium-injected animals. Treatment with the higher dose (1.0 mg/kg) of cadmium chloride for 45 days produced greater metabolic alterations in hepatic tissue than those seen with the lower dose (0.25 mg/kg) given for a shorter period of time (21 days). Discontinuation of cadmium administration for 14 days in rats previously injected with cadmium chloride (1 mg/kg per day) for 21 days, failed to reverse the observed changes in hepatic cAMP or carbohydrate metabolism. A similar persistence of metabolic alterations was noted in rats treated with cadmium (1 mg/kg per day) for 45 days and subsequently maintained without additional treatment for 28 days. Administration of an acute dose of cadmium chloride (60 mg/kg) decreased hepatic phosphodiesterase activity and glycogen content 1 h after the injection. In addition, acute cadmium exposure increased blood glucose, serum urea, and hepatic cAMP levels, and produced an augmentation of basal- and fluoride-activated AC. However, the activities of various hepatic gluconeogenic enzymes remained unaffected in animals given an acute dose of cadmium chloride (60 mg/kg). Data provide evidence that suggests that the gluconeogenic potential of liver is markedly enhanced following chronic exposure to cadmium and that the cadmium-induced changes in carbohydrate metabolism may be associated with an enhanced synthesis of cAMP. In addition, the present study shows that the cadmium-induced metabolic alterations persist even after the cessation of cadmium treatment for a period of 28 days.

In ongoing discussions surrounding the issue of human security, the security of individuals has become entangled in conceptual debates that are preoccupied with notions of appropriate variables, measurements and issue areas. This article suggests and illustrates a basis for human security research that is distinct from such objectivist empiricism. A case study of crisis centres in northwest Russia is used to demonstrate that human security is not only a matter for objectified generalizations, but also a question of practices. Feminist security theory and the work of Pierre Bourdieu are used to address methodological concerns raised during fieldwork on crisis centres in northwest Russia. Three dimensions are discussed: the conceptualization of security for the specific-actor approach of crisis centres, the ways in which relevant empirical data are established, and the subsequent interpretation of such data. The discussion shows, first, that rethinking security for crisis centres reveals contingencies in the research process that are relevant to the establishment of human security knowledge; second, the practice of human security research reflects the fragility in the understanding and production of security in everyday contexts. Accordingly, when we examine human security, our analysis ought to be directed at security as an ambiguous practice.

Context:KDT501 is an isohumulone drug that has demonstrated beneficial effects on metabolic parameters in mice.Objective:This study was intended to examine potential improvements in metabolism in humans.Design and Setting:Changes in carbohydrate and lipid metabolism, along with inflammatory markers, were evaluated in prediabetic humans in a clinical research center.Participants:Nine obese patients participated. All had prediabetes or normal glucose tolerance plus three features of metabolic syndrome.Intervention:All participants were treated with escalating doses of KDT501 to a maximum dose of 1000 mg every 12 hours for a total of 28 days.Outcome Measures:Changes in carbohydrate metabolism were measured with oral glucose tolerance, homeostatic model of insulin resistance, and euglycemic clamp; changes in plasma lipids and response to a lipid tolerance test; and changes in plasma inflammatory markers.Results:The drug was well tolerated. After KDT501 treatment, plasma triglycerides were reduced at 4 hours during a lipid tolerance test. Furthermore, plasma adiponectin and high-molecular-weight adiponectin increased significantly, and plasma tumor necrosis factor-α decreased significantly. There were no significant changes in oral glucose tolerance test results or insulin sensitivity measures.Conclusions:Despite the small sample size and the short duration of therapy, KDT501 administration reduced measures of systemic inflammation and improved postmeal plasma triglyceride levels, which may be beneficial in participants with insulin resistance or metabolic syndrome.

In Ukraine, among the causes of death because of digestive tract diseases, alcoholic liver disease (ALD) has the second place. Due to the significant prevalence of obesity and the growing incidence of ALD, methods are being sought to prevent the progression of the pathological process in the liver, the occurrence of complications and to improve the quality of life of such patients. The aim of the study: to examine the effect of complex treatment with ademethionine, arginine glutamate and rosuvastatin on changes in lipid and carbohydrate metabolism in patients with alcoholic liver cirrhosis (ALC) in combination with obesity. Methods. The study included 156 patients diagnosed with ALC in combination with obesity, including 18 women and 138 men aged (45.3±8.9) years and a median duration of disease (5.1±2.8) years. Patients were divided into subgroups depending on the stage of Child-Pugh decompensation and depending on the applied treatment. Results. At the stage of decompensation, lipid metabolism and leptin levels were low, which indicates the depletion of body fat depots as the disease progresses. It may be due to the progression of the liver dysfunction, as it is actively involved in regulating the formation, destruction and accumulation of fats. Changes in carbohydrate metabolism in patients with ALC in combination with obesity were characterized by a significant increase in IRI, HOMA-IR index and a decrease in the QUICKI index, indicating the presence of insulin resistance (p<0.05). In determining the adipocytokine values, it was found that in decompensated liver function, the leptin rates decreased and the levels of adiponectin increased. Higher leptin content in the stage of compensation and subcompensation is also associated with increased secretion of adipose tissue. At the stage of decompensation, fat depots are depleted, so leptin levels are reduced. This decrease is directly related to the Child-Pugh and MELD scores. Adiponectin levels were decreased in the stage of compensation and increased with the progression of the disease and correlated with disease severity and the MELD score. It is thought that an increased adiponectin level indicates the level of anti-inflammatory reaction in response to hepatocyte damage. Significant deterioration in carbohydrate metabolism, adiponectin and leptin in patients receiving basic treatment was accompanied by deterioration of their condition and increased the risk of 3-month mortality. After the course of treatment in patients of group receiving ademethionine, arginine, glutamate and rosuvastatin at the stage of compensation and subcompensation, the rates of lipid, carbohydrate metabolism, adiponectin and leptin significantly improved and differed from those in patients receiving basic treatment and combination of basic treatment, ademethionine and arginine glutamate (p<0.05). At the stage of decompensation in the scheme with the inclusion of rosuvastatin it was possible to normalize the levels of HDL cholesterol, VLDL cholesterol, atherogenic coefficient and leptin, reduce the levels of adiponectin, IRI, HOMA-IR, HbA1c and increase the QUICKI index, which was accompanied by a decrease in Child-Pugh severity score and 3 month mortality MELD score. Conclusions. In patients with ALC in combination with obesity, the inclusion in the treatment of ademethionine, arginine glutamate and rosuvastatin helps to improve the course of the disease according to the lipid and carbohydrate metabolism, Child-Pugh and MELD scores.

Aim. To study the associations of angiotensinogen (AGT) (s4762(С521Т), rs699(Т704C)) and angiotensin II receptor type I (AGTR1) (rs5186(A1166C)) genetic polymorphisms with serum levels of insulin, glucagon, C-peptide, leptin, as well as with dyslipidemia and glycemic levels in Dagestan residents with combination of type 2 diabetes (T2D) and hypertension (HTN), as well as with isolated T2D/HTN.Material and methods. We examined 16 patients with isolated T2D, 59 patients with T2D+HTN and 51 patients with isolated HTN from Dagestan. Genetic polymorphisms of the AGT and AGTR1 genes were studied. The levels of insulin, glucagon, C-peptide, and leptin were studied by enzyme-linked immunosorbent assay (ELISA), while lipid and carbohydrate metabolism — by biochemical methods.Results. In patients with T2D, the association of CC genotype of AGT gene rs4762(С521Т) polymorphism with a leptin decrease was determined, while its CT genotype was associated with an increase in serum level of triglycerides. The TC genotype of AGT gene rs699(Т704C) polymorphism was associated with an increase in leptin, triglyceride and glucose levels. The AA genotype of AGTR1 gene rs5186(A1166C) polymorphism was associated with an increase in insulin and glucose levels, as well as a decrease in leptin level. In patients with a combination of T2D and HTN, CC and CT genotypes of AGT gene rs4762(С521Т) polymorphism was associated with a decrease in glucagon level. The TT genotype of AGT gene rs699(Т704C) polymorphism was associated with an increase in insulin, triglyceride, glucose and body mass index (BMI) levels. In isolated HTN, the CC and CT genotypes of AGT gene rs4762(С521Т) polymorphism were associated ith a decrease in glucagon level. The TT genotype of AGT gene rs699(Т704C) polymorphism was associated with increased levels of insulin, low density lipoproteins, and BMI.Conclusion. Associations of AGT (s4762(С521Т), rs699(Т704C)) and AGTR1 (rs5186(A1166C)) genetic polymorphisms with carbohydrate and lipid metabolism changes are an important pathogenetic link of T2D and HTN, which allows developing an individual prognosis of these diseases in Dagestan residents.

The value of hemoglobin A1c for diagnosis of diabetes mellitus and other changes in carbohydrate metabolism in women with recent gestational diabetes mellitus

The use of a combination of myoinositol and D-chiroinositol in a ratio of 5:1 (MI/DCI 5:1), manganese and folic acid appears promising for the correction of androgen-dependent dermopathy, regulation of the menstrual cycle, restoration of ovulation in patients planning pregnancy, as well as for improving endocrine and metabolic parameters, carbohydrate and lipid metabolism in patients with polycystic ovary syndrome (PCOS). Objective. To compare the effects of combined oral contraceptives (COCs) and combination of MI/DCI 5:1, manganese and folic acid on endocrine, metabolic and clinical parameters in patients with PCOS. Patients and methods. A prospective open-label clinical trial included 129 patients with PCOS. Patients in group 1 (A, n = 63) were prescribed COCs with antiandrogenic activity containing ethinyl estradiol 20 μg/drospirenone 3 mg; patients in group 2 (B, n = 66) were prescribed the combination of MI/DCI 5:1, manganese and folic acid for 6 months. Lifestyle modifications were also recommended for all patients: physical activity and diet therapy. Results. Low serum androgen levels were observed in both groups. The use of COCs resulted in a more significant reduction in hirsutism according to the Ferriman-Gallwey score and clinical manifestations of acne. Administration of the combination of MI/DCI 5:1 showed good results in improving carbohydrate and lipid metabolism in patients with PCOS. Thus, in group B there was a significant reduction in glucose levels (4.9 ± 0.3 vs. 5.2 ± 0.5 mmol/L, p < 0.01) and fasting insulin (12.1 ± 5.3 vs. 22.2 ± 4.9 mmol/L, p < 0.01), HOMA and CARO indices. No changes in carbohydrate metabolism were observed during COCs administration, but there was an increase in cholesterol levels (6.0 ± 0.7 vs. 5.7 ± 0.5 mmol/L, p < 0.05), low-density lipoproteins (LDL) (3.9 ± 0.4 vs. 3.5 ± 0.6 mmol/L, p < 0.05), and atherogenic coefficient (AC). Lipid profile parameters in group B improved significantly from baseline by reducing cholesterol (5.1 ± 0.6 vs. 5.6 ± 0.6 mmol/L, p < 0.05), triglycerides (1.5 ± 0.4 vs. 1.8 ± 0.3 mmol/L, p < 0.05), and LDL (2.7 ± 0.5 vs. 3.6 ± 0.8 mmol/L, p < 0.01). Diet therapy and administration of the combination of MI/DCI 5:1, manganese and folic acid resulted in a 4.4% decrease in waist circumference and a 4.8% decrease in body mass index (BMI). In contrast, the COCs group showed a 2.1% increase in waist circumference and a 4.7% increase in BMI, which may be related to an increased appetite. In group B, the regularity of menstrual cycle in patients with PCOS was also analyzed. After 6 months of therapy, a regular cycle was observed in 40% of patients vs. 11% of patients at baseline with a mean duration of 33.3 ± 9.4 days (p < 0.05). Conclusion. Lifestyle modification with the combination of MI/DCI 5:1, manganese and folic acid is effective for the correction of endocrine, metabolic, and clinical profile in patients with PCOS and appears to be a promising new alternative to COCs regardless of reproductive planning. Key words: polycystic ovary syndrome, myoinositol, D-chiroinositol, hyperandrogenism, insulin resistance, hirsutism, acne

Aim — to determine the changes in carbohydrate metabolism in case of intact gallbladder(GB) and its disorders including the condition after cholecystectomy in patients with coronary heart disease (CHD). Materials and methods. Examinations involved 71 inpatients (52.11 % males, 47.89 % females, median age 65 years) with various forms of CHD (acute coronary syndrome, acute myocardial infarction, postinfarction cardiosclerosis), who were treated in cardiological and infarctional wards. All patients were divided into groups depending on the sonographically determined GB status: the 1st group (n = 30) with intact GB, 2ndgroup (n = 24) with inflections, sludge or signs of chronic cholecystitis, the 3rd group (n = 7) withcholelithiasis and calculous cholecystitis, the 4th(n = 10) with the history of cholecystectomy. Thegroupswereage- and no­sology-matching. Apart from routine investigations, 20 parameters of glucose metabolism were determined: oral glucosetolerance test (OGTT) with the estimation of glucose, insulin and C-peptide levels at baseline (0’) and on 30, 60 and 120 minutes after taking of 75 g of glucose; glycated hemoglobin(НbА1c) levels; increasing areas under curves in the early and late phases for glucose (iAUCG 0-30’, 30-120’) and insulin (iAUCI 0-30’, 30-120’); seevral indexes (HOMA-IR, Quicki, Matsuda, Shuster, DeFronzo). Results. It has been established that GB disorders were accompanied by the significantly less frequent normal glucose metabolism (6.4 % vs 26.7 %) and higher diabetes incidence (19.4 % vs 3.3 %, both p < 0.05) compared to the intact GB. GB condition did not affect the liver insulin sensitivity, the peripheral tissues’ insulin sensitivity, liver clearance of insulin, C-peptide level, as well as the early or late insulin secretion phase, although it was significantly associated with glycemia levels, glycated hemoglobin and the ratio between insulin secretion and the tissue sensitivity. The worst condition of carbohydrate metabolism was observed in case of sludge, GB deformations and signs of chronic cholecystitis: these changes were accompanied by significantly higher glycemia at all points (0’, 30’, 60’, 120’), bigger area under curve for glucose in the late phase (30—120’), higher glycated hemoglobin and lower DeFronzo index. The condition after cholecystectomy was associated with a lower level of glycated hemoglobin, although during the first hour after glucose loading levels of glycemia exceeded the values of people with intact GB. Conclusion. The gallbladder condition affects carbohydrate metabolism, and its pathological changes are associated with a deterioration of carbohydrate balance.

Introduction. The analogue of glucagon-like peptide-1 (GLP-1), liraglutide, has been shown to be effective in reducing body weight. Its effect on lipid and carbohydrate metabolism is still being studied.Aim. To assess the dynamics of body weight, carbohydrate metabolism and lipid profile in obese children using liraglutide.Materials and methods. A single-center, prospective study was conducted to evaluate the use of liraglutide in children aged 12 to 18 years with constitutional exogenous obesity over a period of 12 months. The decrease in body weight, the standard deviation of the body mass index (SDS BMI) and the dynamics of laboratory parameters (glucose, insulin, lipid profile) were evaluated. Results. A decrease in SDS BMI by 0.25 or more was noted in 23 children (71.8%, group 1). Weight loss in group 1 patients was observed from 1 to 8 months of therapy. In group 1 patients, there was a significant decrease in glucose values from 5.0 ± 0.4 to 4.6 ± 0.5 mmol/l (p < 0.0001), fasting insulin from 13.0 ± 7.6 to 8.3 ± 5.7 mMU/l (p = 0.004), HOMA-IR insulin resistance index from 3.4 ± 2.0 to 1.9 ± 1.5 (p = 0.0008). In group 2 patients, who did not experience weight loss, there was a significant reduction in serum cholesterol levels from 4.4 ± 0.8 mmol/l to 3.3 ± 1.6 mmol/l (p = 0.02) and low-density lipoprotein cholesterol levels from 2.1 ± 0.6 mmol/l to 1.7 ± 0.6 mmol/l (p = 0.014).Discussion. In our study, as in previous studies, there was no effect of gender, age, and degree of obesity on the effectiveness of treatment. The obtained significant changes in carbohydrate metabolism and lipid profile in obese children after liraglutide therapy had not been previously observed.Conclusions. In the group of children who did not lose body weight, there was an improvement in lipid metabolism, which requires an additional assessment of the effect of GPP-1 agonists on metabolism. More research is needed to identify factors that affect the effectiveness of liraglutide treatment.

Rapid Changes in Carbohydrate Metabolism in Muscle Induced by Triiodothyronine; the Role of Glucose 1,6-Bisphosphate

Objective: The type of dietary fat as well as the amount of cholesterol occurring in the diet have been associated with several metabolic disorders. Thus, the aim of the present study was to investigate the influence of a hypercholesterolemic diet enriched with coconut oil and cholesterol on carbohydrate and lipid metabolism in a rat model.Methods: Twenty male Wistar rats weighing about 190 g were assigned to two dietary groups. One group received a semipurified control diet and the other was given a diet enriched in coconut oil (25% by weight) and cholesterol (1% by weight) for 26 days.Results: Our results indicated a significant increase in serum total cholesterol (+285%; p<0.001), low-density lipoproteins (+154%; p<0.01), liver cholesterol (+1509%; p<0.001), as well as a significant increase in liver weight (+46%; p<0.001) in those rats fed the hypercholesterolemia-inducing diet as compared to controls. Moreover, a significant decrease in serum high-density lipoproteins (−67%; p<0.001), triacylglycerols levels (−33%; p<0.05), and abdominal fat weight (−39%; p<0.01) were found. The observed alterations in serum lipid and lipoprotein profile resembled a situation of type IIa hyperlipidemia in humans. Measurement of several enzymes concerned with lipid utilization revealed a significant increase in 3-hydroxy-3-methylglutaryl-CoA reductase activity (+68%; p<0.01) in the liver of animals fed the hypercholesterolemic diet, while a significant reduction in plasma lecithin-cholesterol acyltransferase activity (−66%; p<0.001) was found. The situation of hypoglycemia (−18%; p<0.05) was accompanied by lower levels of serum insulin (−45%; p<0.01) and liver glycogen (−30%; p<0.05) in the hypercholesterolemic rats. Furthermore, glucose utilization was altered since lower glucose-6-Pase (−33%; p<0.05) and increased glucokinase (+212%; p<0.001) activities in the liver were found in the rat model of hypercholesterolemia.Conclusion: These results provide new evidence that a diet-induced hypercholesterolemia in rats is associated with several adaptative changes in carbohydrate metabolism. These findings may be of importance not only considering the role of western diets on cholesterogenesis, but also in other metabolic disturbances involving lipid and carbohydrate metabolism.

Utilidad de la hemoglobina A1c en el diagnóstico de diabetes mellitus y otras alteraciones del metabolismo glucídico en mujeres con diabetes mellitus gestacional reciente

Changes in carbohydrate metabolism during 30 months on Norplant R

Gestational diabetes mellitus (GDM) occurs due to the inability to adapt to physiologically observed changes in carbohydrate metabolism during pregnancy. Neudesin is a multi-functional secreted protein suggested to have a crucial regulator role in energy and carbohydrate metabolism. This study aimed to evaluate maternal serum and umbilical cord neudesin levels in pregnancies with GDM. Twenty-four singleton pregnancies with GDM were compared with gestational age-matched 23 uncomplicated pregnancies in this cross-sectional study. In comparison to the control group, significantly higher maternal serum and umbilical cord neudesin levels were observed in pregnancies with GDM (p < .001). Maternal serum and umbilical cord neudesin levels were also significantly positively correlated with maternal serum insulin levels and HOMA-IR values in the study group (p < .001). Neudesin, with its regulator role in carbohydrate metabolism, may be a contributing factor in the pathophysiology of GDM and may be a target of strategies for the prevention and treatment of GDM. Impact statement What is already known on this subject? Progressive changes in carbohydrate metabolism occur in normal pregnancy to provide continuous nutritional supply to the developing foetus and pregnant woman. When these progressive metabolic changes cannot be compensated, gestational diabetes mellitus (GDM) occurs. What the results of this study add? This is the first study to provide information about maternal serum and umbilical cord neudesin levels in pregnancies with GDM. This study observed that the serum levels of neudesin, which is suggested to have a regulator role in carbohydrate metabolism, were increased in pregnant women with GDM. What the implications are of these findings for clinical practice and/or future research? Neudesin may contribute to impaired carbohydrate metabolism in pregnancies with GDM and can be the subject of further studies on the prevention and treatment of GDM.

Temporal changes in liver carbohydrate metabolism associated with seawater transfer in Oreochromis mossambicus